Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC).
David A. Braun(Yale Cancer Center), David Sommerhalder(Texas Oncology), Martin Gutierrez(Hackensack University Medical Center), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center), Ryan H. Moy(Columbia University Irving Medical Center), Arif Hussain, J Haas, Daria Chabas, Sue Dasen, Marcus Smith Noel(University of Rochester), Anita Scheuber(Nimbus (Italy)), Kurt C. Demel(HealthPartners), Sritama Nath(University of North Carolina at Charlotte), Xinyan Zhang(Obstetrics and Gynecology Hospital of Fudan University), Sunil Sharma, Rama Balaraman(Cardiovascular Institute of Central Florida), Scott R. Daigle(Epizyme (United States)), P. Vijay Kumar(University of Southern California), Julio Antonio Peguero(Hematology Oncology Consultants), GiNell Elliott(Boston Biomedical Research Institute)
Cited by 1
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
|Pharmacology & Therapeutics|2016|921
MUC1: a multifaceted oncoprotein with a key role in cancer progression
|Trends in Molecular Medicine|2014|854
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|Cancer Cell|2021|624